Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia.

Leukemia research reports

Toft-Petersen M, Kjeldsen E, Nederby L, Grønbæk K, Hokland P, Roug AS.
PMID: 25473623
Leuk Res Rep. 2014 Nov 13;3(2):94-7. doi: 10.1016/j.lrr.2014.09.002. eCollection 2014.

We have identified a novel 7.7 Mb del(8)(q23.2q24.11) in a patient progressing to acute myeloid leukemia (AML) following a 12-year stable phase of chronic myelomonocytic leukemia (CMML). A surprisingly high JAK2+ allelic burden of 92% at the time of...

Cite
Toft-Petersen M, Kjeldsen E, Nederby L, et al. A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia. Leuk Res Rep. 2014;3(2):94-7doi: 10.1016/j.lrr.2014.09.002.
Toft-Petersen, M., Kjeldsen, E., Nederby, L., Grønbæk, K., Hokland, P., & Roug, A. S. (2014). A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia. Leukemia research reports, 3(2), 94-7. https://doi.org/10.1016/j.lrr.2014.09.002
Toft-Petersen, Marie, et al. "A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia." Leukemia research reports vol. 3,2 (2014): 94-7. doi: https://doi.org/10.1016/j.lrr.2014.09.002
Toft-Petersen M, Kjeldsen E, Nederby L, Grønbæk K, Hokland P, Roug AS. A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia. Leuk Res Rep. 2014 Nov 13;3(2):94-7. doi: 10.1016/j.lrr.2014.09.002. eCollection 2014. PMID: 25473623; PMCID: PMC4250842.
Copy Download .nbib Format: NLM
Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm.

Leukemia research reports

Herborg LL, Nederby L, Kjeldsen E, Grønbæk K, Hokland P, Hansen M, Celik Hansen M, Roug AS.
PMID: 24371780
Leuk Res Rep. 2013 Jul 04;2(2):51-3. doi: 10.1016/j.lrr.2013.06.001. eCollection 2013.

Chronic myeloid neoplasms have susceptibility to transform into acute myeloid leukemia due to attainment of additional molecular lesions. We here describe the kinetics of a del(7q) driven leukemogenesis in a patient with multiple TET2 mutations and JAK2 V617F mutated...

Cite
Herborg LL, Nederby L, Kjeldsen E, et al. Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm. Leuk Res Rep. 2013;2(2):51-3doi: 10.1016/j.lrr.2013.06.001.
Herborg, L. L., Nederby, L., Kjeldsen, E., Grønbæk, K., Hokland, P., Hansen, M., Celik Hansen, M., & Roug, A. S. (2013). Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm. Leukemia research reports, 2(2), 51-3. https://doi.org/10.1016/j.lrr.2013.06.001
Herborg, Laura Laine, et al. "Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm." Leukemia research reports vol. 2,2 (2013): 51-3. doi: https://doi.org/10.1016/j.lrr.2013.06.001
Herborg LL, Nederby L, Kjeldsen E, Grønbæk K, Hokland P, Hansen M, Celik Hansen M, Roug AS. Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm. Leuk Res Rep. 2013 Jul 04;2(2):51-3. doi: 10.1016/j.lrr.2013.06.001. eCollection 2013. PMID: 24371780; PMCID: PMC3850390.
Copy Download .nbib Format: NLM
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.

Blood cancer journal

Tobiasson M, Dybedahl I, Holm MS, Karimi M, Brandefors L, Garelius H, Grövdal M, Högh-Dufva I, Grønbæk K, Jansson M, Marcher C, Nilsson L, Kittang AO, Porwit A, Saft L, Möllgård L, Hellström-Lindberg E.
PMID: 24608733
Blood Cancer J. 2014 Mar 07;4:e189. doi: 10.1038/bcj.2014.8.

This prospective phase II study evaluated the efficacy of azacitidine (Aza)+erythropoietin (Epo) in transfusion-dependent patients with lower-risk myelodysplastic syndrome (MDS). Patients ineligible for or refractory to full-dose Epo+granulocyte colony stimulation factors for >8 weeks and a transfusion need of...

Cite
Tobiasson M, Dybedahl I, Holm MS, et al. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. Blood Cancer J. 2014;4:e189doi: 10.1038/bcj.2014.8.
Tobiasson, M., Dybedahl, I., Holm, M. S., Karimi, M., Brandefors, L., Garelius, H., Grövdal, M., Högh-Dufva, I., Grønbæk, K., Jansson, M., Marcher, C., Nilsson, L., Kittang, A. O., Porwit, A., Saft, L., Möllgård, L., & Hellström-Lindberg, E. (2014). Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. Blood cancer journal, 4e189. https://doi.org/10.1038/bcj.2014.8
Tobiasson, M, et al. "Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial." Blood cancer journal vol. 4 (2014): e189. doi: https://doi.org/10.1038/bcj.2014.8
Tobiasson M, Dybedahl I, Holm MS, Karimi M, Brandefors L, Garelius H, Grövdal M, Högh-Dufva I, Grønbæk K, Jansson M, Marcher C, Nilsson L, Kittang AO, Porwit A, Saft L, Möllgård L, Hellström-Lindberg E. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. Blood Cancer J. 2014 Mar 07;4:e189. doi: 10.1038/bcj.2014.8. PMID: 24608733; PMCID: PMC3972706.
Copy Download .nbib Format: NLM
The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy.

Clinical Medicine Insights. Oncology

Hägerström E, Lindberg L, Bentzen J, Brødbæk K, Zerahn B, Kristensen B.
PMID: 30670924
Clin Med Insights Oncol. 2019 Jan 07;13:1179554918821320. doi: 10.1177/1179554918821320. eCollection 2019.

INTRODUCTION: Cisplatin is used as treatment for several different malignancies and a well-known complication is irreversible kidney damage. To protect the kidneys, this treatment is often combined with mannitol infusion to promote osmotic diuresis. Earlier studies investigating the nephroprotective...

Cite
Hägerström E, Lindberg L, Bentzen J, et al. The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy. Clin Med Insights Oncol. 2019;13:1179554918821320doi: 10.1177/1179554918821320.
Hägerström, E., Lindberg, L., Bentzen, J., Brødbæk, K., Zerahn, B., & Kristensen, B. (2019). The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy. Clinical Medicine Insights. Oncology, 131179554918821320. https://doi.org/10.1177/1179554918821320
Hägerström, Erik, et al. "The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy." Clinical Medicine Insights. Oncology vol. 13 (2019): 1179554918821320. doi: https://doi.org/10.1177/1179554918821320
Hägerström E, Lindberg L, Bentzen J, Brødbæk K, Zerahn B, Kristensen B. The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy. Clin Med Insights Oncol. 2019 Jan 07;13:1179554918821320. doi: 10.1177/1179554918821320. eCollection 2019. PMID: 30670924; PMCID: PMC6327333.
Copy Download .nbib Format: NLM
Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets.

NAR cancer

Krogh N, Asmar F, Côme C, Munch-Petersen HF, Grønbæk K, Nielsen H.
PMID: 34316692
NAR Cancer. 2020 Dec 22;2(4):zcaa035. doi: 10.1093/narcan/zcaa035. eCollection 2020 Dec.

Cancer cells are addicted to ribosome biogenesis and high levels of translation. Thus, differential inhibition of cancer cells can be achieved by targeting aspects of ribosome biogenesis or ribosome function. Using RiboMeth-seq for profiling of the ∼112 2'-O-Me sites...

Cite
Krogh N, Asmar F, Côme C, et al. Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets. NAR Cancer. 2020;2(4):zcaa035doi: 10.1093/narcan/zcaa035.
Krogh, N., Asmar, F., Côme, C., Munch-Petersen, H. F., Grønbæk, K., & Nielsen, H. (2020). Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets. NAR cancer, 2(4), zcaa035. https://doi.org/10.1093/narcan/zcaa035
Krogh, Nicolai, et al. "Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets." NAR cancer vol. 2,4 (2020): zcaa035. doi: https://doi.org/10.1093/narcan/zcaa035
Krogh N, Asmar F, Côme C, Munch-Petersen HF, Grønbæk K, Nielsen H. Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets. NAR Cancer. 2020 Dec 22;2(4):zcaa035. doi: 10.1093/narcan/zcaa035. eCollection 2020 Dec. PMID: 34316692; PMCID: PMC8210301.
Copy Download .nbib Format: NLM
Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.

Leukemia

Dahl M, Husby S, Eskelund CW, Besenbacher S, Fjelstrup S, Côme C, Ek S, Kolstad A, Räty R, Jerkeman M, Geisler CH, Kjems J, Kristensen LS, Grønbæk K.
PMID: 34244612
Leukemia. 2021 Jul 09; doi: 10.1038/s41375-021-01311-4. Epub 2021 Jul 09.

Mantle cell lymphoma (MCL) is characterized by marked differences in outcome, emphasizing the need for strong prognostic biomarkers. Here, we explore expression patterns and prognostic relevance of circular RNAs (circRNAs), a group of endogenous non-coding RNA molecules, in MCL....

Cite
Dahl M, Husby S, Eskelund CW, et al. Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. Leukemia. 2021;doi: 10.1038/s41375-021-01311-4.
Dahl, M., Husby, S., Eskelund, C. W., Besenbacher, S., Fjelstrup, S., Côme, C., Ek, S., Kolstad, A., Räty, R., Jerkeman, M., Geisler, C. H., Kjems, J., Kristensen, L. S., & Grønbæk, K. (2021). Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. Leukemia, . https://doi.org/10.1038/s41375-021-01311-4
Dahl, Mette, et al. "Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials." Leukemia vol. (2021). doi: https://doi.org/10.1038/s41375-021-01311-4
Dahl M, Husby S, Eskelund CW, Besenbacher S, Fjelstrup S, Côme C, Ek S, Kolstad A, Räty R, Jerkeman M, Geisler CH, Kjems J, Kristensen LS, Grønbæk K. Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. Leukemia. 2021 Jul 09; doi: 10.1038/s41375-021-01311-4. Epub 2021 Jul 09. PMID: 34244612.
Copy Download .nbib Format: NLM
The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records.

Clinical epidemiology

Lauritsen TB, Nørgaard JM, Grønbæk K, Vallentin AP, Ahmad SA, Hannig LH, Severinsen MT, Adelborg K, Østgård LSG.
PMID: 34163252
Clin Epidemiol. 2021 Jun 14;13:439-451. doi: 10.2147/CLEP.S306857. eCollection 2021.

BACKGROUND: The Danish Myelodysplastic Syndromes Database (DMDSD) comprises nearly all patients diagnosed with myelodysplastic syndromes (MDS) in Denmark since 2010. The DMDSD has not yet been used for epidemiological research and the quality of registered variables remains to be...

Cite
Lauritsen TB, Nørgaard JM, Grønbæk K, et al. The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records. Clin Epidemiol. 2021;13:439-451doi: 10.2147/CLEP.S306857.
Lauritsen, T. B., Nørgaard, J. M., Grønbæk, K., Vallentin, A. P., Ahmad, S. A., Hannig, L. H., Severinsen, M. T., Adelborg, K., & Østgård, L. S. G. (2021). The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records. Clinical epidemiology, 13439-451. https://doi.org/10.2147/CLEP.S306857
Lauritsen, Tine Bichel, et al. "The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records." Clinical epidemiology vol. 13 (2021): 439-451. doi: https://doi.org/10.2147/CLEP.S306857
Lauritsen TB, Nørgaard JM, Grønbæk K, Vallentin AP, Ahmad SA, Hannig LH, Severinsen MT, Adelborg K, Østgård LSG. The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records. Clin Epidemiol. 2021 Jun 14;13:439-451. doi: 10.2147/CLEP.S306857. eCollection 2021. PMID: 34163252; PMCID: PMC8213953.
Copy Download .nbib Format: NLM
Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial.

Cancer immunology, immunotherapy : CII

Holmberg-Thydén S, Dufva IH, Gang AO, Breinholt MF, Schejbel L, Andersen MK, Kadivar M, Svane IM, Grønbæk K, Hadrup SR, El Fassi D.
PMID: 34218294
Cancer Immunol Immunother. 2021 Jul 04; doi: 10.1007/s00262-021-02993-6. Epub 2021 Jul 04.

BACKGROUND: Standard care for patients with high-risk myelodysplastic syndrome (MDS) is hypomethylating agents such as azacitidine (AZA), which can induce expression of methylated tumor-associated antigens and therefore potentiate immunotherapeutic targeting.METHOD: In this phase 1 trial, we combined AZA with...

Cite
Holmberg-Thydén S, Dufva IH, Gang AO, et al. Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial. Cancer Immunol Immunother. 2021;doi: 10.1007/s00262-021-02993-6.
Holmberg-Thydén, S., Dufva, I. H., Gang, A. O., Breinholt, M. F., Schejbel, L., Andersen, M. K., Kadivar, M., Svane, I. M., Grønbæk, K., Hadrup, S. R., & El Fassi, D. (2021). Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial. Cancer immunology, immunotherapy : CII, . https://doi.org/10.1007/s00262-021-02993-6
Holmberg-Thydén, Staffan, et al. "Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial." Cancer immunology, immunotherapy : CII vol. (2021). doi: https://doi.org/10.1007/s00262-021-02993-6
Holmberg-Thydén S, Dufva IH, Gang AO, Breinholt MF, Schejbel L, Andersen MK, Kadivar M, Svane IM, Grønbæk K, Hadrup SR, El Fassi D. Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial. Cancer Immunol Immunother. 2021 Jul 04; doi: 10.1007/s00262-021-02993-6. Epub 2021 Jul 04. PMID: 34218294.
Copy Download .nbib Format: NLM
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population.

Transplantation and cellular therapy

Wedge E, Hansen JW, Dybedal I, Creignou M, Ejerblad E, Lorenz F, Werlenius O, Ungerstedt J, Holm MS, Nilsson L, Kittang AO, Antunovic P, Rohon P, Andersen MK, Papaemmanuil E, Bernard E, Jädersten M, Hellström-Lindberg E, Grønbæk K, Ljungman P, Friis LS.
PMID: 34500124
Transplant Cell Ther. 2021 Sep 06; doi: 10.1016/j.jtct.2021.08.028. Epub 2021 Sep 06.

Chronic myelomonocytic leukemia (CMML) is an aggressive disease in which survival after allogeneic hematopoietic stem cell transplantation (HCT) remains relatively poor. An assessment of prognostic factors is an important part of treatment decision making and has the potential to...

Cite
Wedge E, Hansen JW, Dybedal I, et al. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population. Transplant Cell Ther. 2021;doi: 10.1016/j.jtct.2021.08.028.
Wedge, E., Hansen, J. W., Dybedal, I., Creignou, M., Ejerblad, E., Lorenz, F., Werlenius, O., Ungerstedt, J., Holm, M. S., Nilsson, L., Kittang, A. O., Antunovic, P., Rohon, P., Andersen, M. K., Papaemmanuil, E., Bernard, E., Jädersten, M., Hellström-Lindberg, E., Grønbæk, K., Ljungman, P., & Friis, L. S. (2021). Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2021.08.028
Wedge, Eileen, et al. "Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population." Transplantation and cellular therapy vol. (2021). doi: https://doi.org/10.1016/j.jtct.2021.08.028
Wedge E, Hansen JW, Dybedal I, Creignou M, Ejerblad E, Lorenz F, Werlenius O, Ungerstedt J, Holm MS, Nilsson L, Kittang AO, Antunovic P, Rohon P, Andersen MK, Papaemmanuil E, Bernard E, Jädersten M, Hellström-Lindberg E, Grønbæk K, Ljungman P, Friis LS. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population. Transplant Cell Ther. 2021 Sep 06; doi: 10.1016/j.jtct.2021.08.028. Epub 2021 Sep 06. PMID: 34500124.
Copy Download .nbib Format: NLM
Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.

Leukemia research reports

Andersen CL, Asmar F, Klausen T, Hasselbalch H, Grønbæk K.
PMID: 24371765
Leuk Res Rep. 2012 Dec 08;2(1):1-3. doi: 10.1016/j.lrr.2012.10.002. eCollection 2012.

Heterogeneous clinical responses to histone deacetylase inhibitors (HDACi) in diffuse large B-cell lymphoma (DLBCL) have prompted a need for evaluating the impact of mutations in the histone acetyl transferases (HAT) CREBBP and EP300 on HDACi treatment outcome. We identified...

Cite
Andersen CL, Asmar F, Klausen T, et al. Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leuk Res Rep. 2012;2(1):1-3doi: 10.1016/j.lrr.2012.10.002.
Andersen, C. L., Asmar, F., Klausen, T., Hasselbalch, H., & Grønbæk, K. (2012). Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leukemia research reports, 2(1), 1-3. https://doi.org/10.1016/j.lrr.2012.10.002
Andersen, Christen Lykkegaard, et al. "Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones." Leukemia research reports vol. 2,1 (2012): 1-3. doi: https://doi.org/10.1016/j.lrr.2012.10.002
Andersen CL, Asmar F, Klausen T, Hasselbalch H, Grønbæk K. Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leuk Res Rep. 2012 Dec 08;2(1):1-3. doi: 10.1016/j.lrr.2012.10.002. eCollection 2012. PMID: 24371765; PMCID: PMC3850379.
Copy Download .nbib Format: NLM
Synthesis of Dibenzotropones by Alkyne-Carbonyl Metathesis.

The Journal of organic chemistry

Sobhani M, Frey A, Rettmann A, Thom R, Villinger A, Ehlers P, Langer P, Sonne T, Obel C, Grønbæk K.
PMID: 34708654
J Org Chem. 2021 Nov 05;86(21):14420-14432. doi: 10.1021/acs.joc.1c01132. Epub 2021 Oct 28.

Dibenzocycloheptanones (dibenzotropones) were prepared by Brønsted acid mediated intramolecular alkyne-carbonyl metathesis (ACM) reactions. The cyclization precursors are readily available by Sonogashira reaction of 2-bromobenzoyl chloride with terminal alkynes, followed by Suzuki reactions with benzaldehydes. The ACM reactions are highly...

Cite
Sobhani M, Frey A, Rettmann A, et al. Synthesis of Dibenzotropones by Alkyne-Carbonyl Metathesis. J Org Chem. 2021;86(21):14420-14432doi: 10.1021/acs.joc.1c01132.
Sobhani, M., Frey, A., Rettmann, A., Thom, R., Villinger, A., Ehlers, P., Langer, P., Sonne, T., Obel, C., & Grønbæk, K. (2021). Synthesis of Dibenzotropones by Alkyne-Carbonyl Metathesis. The Journal of organic chemistry, 86(21), 14420-14432. https://doi.org/10.1021/acs.joc.1c01132
Sobhani, Maryam, et al. "Synthesis of Dibenzotropones by Alkyne-Carbonyl Metathesis." The Journal of organic chemistry vol. 86,21 (2021): 14420-14432. doi: https://doi.org/10.1021/acs.joc.1c01132
Sobhani M, Frey A, Rettmann A, Thom R, Villinger A, Ehlers P, Langer P, Sonne T, Obel C, Grønbæk K. Synthesis of Dibenzotropones by Alkyne-Carbonyl Metathesis. J Org Chem. 2021 Nov 05;86(21):14420-14432. doi: 10.1021/acs.joc.1c01132. Epub 2021 Oct 28. PMID: 34708654.
Copy Download .nbib Format: NLM
Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells.

Cancers

Jakobsen T, Dahl M, Dimopoulos K, Grønbæk K, Kjems J, Kristensen LS.
PMID: 33498476
Cancers (Basel). 2021 Jan 20;13(3). doi: 10.3390/cancers13030365.

Immunomodulatory drugs (IMiDs), such as lenalidomide and pomalidomide, may induce significant remissions in multiple myeloma (MM) patients, but relapses are frequently observed and the underlying molecular mechanisms for this are not completely understood. Circular RNAs (circRNAs) constitute an emerging...

Cite
Jakobsen T, Dahl M, Dimopoulos K, et al. Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells. Cancers (Basel). 2021;13(3)doi: 10.3390/cancers13030365.
Jakobsen, T., Dahl, M., Dimopoulos, K., Grønbæk, K., Kjems, J., & Kristensen, L. S. (2021). Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells. Cancers, 13(3), . https://doi.org/10.3390/cancers13030365
Jakobsen, Theresa, et al. "Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells." Cancers vol. 13,3 (2021). doi: https://doi.org/10.3390/cancers13030365
Jakobsen T, Dahl M, Dimopoulos K, Grønbæk K, Kjems J, Kristensen LS. Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells. Cancers (Basel). 2021 Jan 20;13(3). doi: 10.3390/cancers13030365. PMID: 33498476; PMCID: PMC7930955.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries